{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:09:50Z","timestamp":1794668990224,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7982","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2023,10,12]]},"DOI":"10.1038\/s41586-023-06609-0","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T12:02:17Z","timestamp":1694433737000},"page":"376-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":191,"title":["Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir"],"prefix":"10.1038","volume":"622","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0544-7413","authenticated-orcid":false,"given":"Yinkai","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-6942","authenticated-orcid":false,"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3733-9556","authenticated-orcid":false,"given":"Sho","family":"Iketani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8072-6615","authenticated-orcid":false,"given":"Mengmeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qucheng","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8175-5621","authenticated-orcid":false,"given":"Haofeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Jung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1489-1348","authenticated-orcid":false,"given":"Bruce","family":"Culbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3101-7625","authenticated-orcid":false,"given":"Hiroshi","family":"Mohri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Luck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoce","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-9815","authenticated-orcid":false,"given":"Xiuna","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-8247","authenticated-orcid":false,"given":"Yosef","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-7140","authenticated-orcid":false,"given":"Alejandro","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9679-0582","authenticated-orcid":false,"given":"Stephen P.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-2384","authenticated-orcid":false,"given":"Zihe","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-149X","authenticated-orcid":false,"given":"David D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-3268","authenticated-orcid":false,"given":"Haitao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"6609_CR1","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"6609_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. New Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"New Engl. J. Med."},{"key":"6609_CR3","doi-asserted-by":"publisher","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature https:\/\/doi.org\/10.1038\/s41586-022-05514-2 (2022).","DOI":"10.1038\/s41586-022-05514-2"},{"key":"6609_CR4","doi-asserted-by":"publisher","unstructured":"Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature https:\/\/doi.org\/10.1038\/s41586-022-05053-w (2022).","DOI":"10.1038\/s41586-022-05053-w"},{"key":"6609_CR5","doi-asserted-by":"publisher","unstructured":"Wong, C. K. H. et al. Real-world effectiveness of early molnupiravir or nirmatrelvir\u2013ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: a retrospective cohort study. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(22)00507-2 (2022).","DOI":"10.1016\/S1473-3099(22)00507-2"},{"key":"6609_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMc2207519","volume":"387","author":"E Takashita","year":"2022","unstructured":"Takashita, E. et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N. Engl. J. Med. 387, 468\u2013470 (2022).","journal-title":"N. Engl. J. Med."},{"key":"6609_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMc2206449","volume":"387","author":"ME Charness","year":"2022","unstructured":"Charness, M. E. et al. Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment. N. Engl. J. Med. 387, 1045\u20131047 (2022).","journal-title":"N. Engl. J. Med."},{"key":"6609_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1056\/NEJMc2205944","volume":"387","author":"AS Anderson","year":"2022","unstructured":"Anderson, A. S., Caubel, P. & Rusnak, J. M. Nirmatrelvir-ritonavir and viral load rebound in Covid-19. N. Engl. J. Med. 387, 1047\u20131049 (2022).","journal-title":"N. Engl. J. Med."},{"key":"6609_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cmi.2022.03.030","volume":"28","author":"F Girardin","year":"2022","unstructured":"Girardin, F., Manuel, O., Marzolini, C. & Buclin, T. Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19. Clin. Microbiol. Infect. 28, 1044\u20131046 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"6609_CR10","doi-asserted-by":"publisher","first-page":"e2117142119","DOI":"10.1073\/pnas.2117142119","volume":"119","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2. Proc. Natl Acad. Sci. USA 119, e2117142119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6609_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell 13, 689\u2013693 (2022).","journal-title":"Protein Cell"},{"key":"6609_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"6609_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel, F. & Hance, A. J. HIV drug resistance. N. Engl. J. Med. 350, 1023\u20131035 (2004).","journal-title":"N. Engl. J. Med."},{"key":"6609_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","volume":"22","author":"M Labrie","year":"2022","unstructured":"Labrie, M., Brugge, J. S., Mills, G. B. & Zervantonakis, I. K. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat. Rev. Cancer 22, 323\u2013339 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"6609_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. SARS-CoV-2 variants in patients with immunosuppression. New Engl. J. Med. 385, 562\u2013566 (2021).","journal-title":"New Engl. J. Med."},{"key":"6609_CR16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/s41591-022-01882-4","volume":"28","author":"S Harari","year":"2022","unstructured":"Harari, S. et al. Drivers of adaptive evolution during chronic SARS-CoV-2 infections. Nat. Med. 28, 1501\u20131508 (2022).","journal-title":"Nat. Med."},{"key":"6609_CR17","doi-asserted-by":"publisher","first-page":"100735","DOI":"10.1016\/j.xcrm.2022.100735","volume":"3","author":"A Heyer","year":"2022","unstructured":"Heyer, A. et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep. Med. 3, 100735 (2022).","journal-title":"Cell Rep. Med."},{"key":"6609_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/cid\/ciac769","volume":"76","author":"JI Hogan","year":"2023","unstructured":"Hogan, J. I. et al. Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019. Clin. Infect. Dis. 76, 342\u2013345 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"6609_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29104-y","volume":"13","author":"S Gandhi","year":"2022","unstructured":"Gandhi, S. et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat. Commun. 13, 1547 (2022).","journal-title":"Nat. Commun."},{"key":"6609_CR20","doi-asserted-by":"publisher","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","volume":"73","author":"M Martinot","year":"2021","unstructured":"Martinot, M. et al. Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019. Clin. Infect. Dis. 73, e1762\u2013e1765 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"6609_CR21","doi-asserted-by":"publisher","first-page":"30494","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","volume":"22","author":"Y Shu","year":"2017","unstructured":"Shu, Y. & McCauley, J. GISAID: Global Initiative on Sharing All Influenza Data - from vision to reality. Eurosurveillance 22, 30494 (2017).","journal-title":"Eurosurveillance"},{"key":"6609_CR22","unstructured":"Xocova\u00ae (ensitrelvir fumaric acid) tablets 125mg approved in Japan for the treatment of SARS-COV-2 infection, under the Emergency Regulatory Approval System. Shionogi https:\/\/www.shionogi.com\/global\/en\/news\/2022\/11\/e20221122.html (2022)."},{"key":"6609_CR23","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"6609_CR24","doi-asserted-by":"publisher","first-page":"e0069722","DOI":"10.1128\/aac.00697-22","volume":"66","author":"H Mukae","year":"2022","unstructured":"Mukae, H. et al. A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part. Antimicrob. Agents Chemother. 66, e0069722 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"6609_CR25","doi-asserted-by":"publisher","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature https:\/\/doi.org\/10.1038\/s41586-022-04980-y (2022).","DOI":"10.1038\/s41586-022-04980-y"},{"key":"6609_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"6609_CR27","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1093\/cid\/ciab1041","volume":"75","author":"L Lu","year":"2022","unstructured":"Lu, L. et al. Neutralization of severe acute respiratory syndrome coronavirus 2 Omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. Clin. Infect. Dis. 75, e822\u2013e826 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"6609_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","volume":"55","author":"P Halfon","year":"2011","unstructured":"Halfon, P. & Locarnini, S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 55, 192\u2013206 (2011).","journal-title":"J. Hepatol."},{"key":"6609_CR29","doi-asserted-by":"publisher","first-page":"2270012","DOI":"10.1002\/smsc.202270012","volume":"2","author":"B Zhong","year":"2022","unstructured":"Zhong, B. et al. Oridonin inhibits SARS-CoV-2 by targeting Its 3C-like protease. Small Sci. 2, 2270012 (2022).","journal-title":"Small Sci."},{"key":"6609_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jmb.2006.11.073","volume":"366","author":"X Xue","year":"2007","unstructured":"Xue, X. et al. Production of authentic SARS-CoV Mpro with enhanced activity: application as a novel Tag-cleavage endopeptidase for protein overproduction. J. Mol. Biol. 366, 965\u2013975 (2007).","journal-title":"J. Mol. Biol."},{"key":"6609_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. D 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"6609_CR32","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"6609_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"6609_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. D"},{"key":"6609_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29413-2","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat. Commun. 13, 1891 (2022).","journal-title":"Nat. Commun."},{"key":"6609_CR36","doi-asserted-by":"publisher","first-page":"e02168-20","DOI":"10.1128\/mBio.02168-20","volume":"11","author":"C Ye","year":"2020","unstructured":"Ye, C. et al. Rescue of SARS-CoV-2 from a single bacterial artificial chromosome. mBio 11, e02168-20 (2020).","journal-title":"mBio"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06609-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T08:10:06Z","timestamp":1697011806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":36,"journal-issue":{"issue":"7982","published-print":{"date-parts":[[2023,10,12]]}},"alternative-id":["6609"],"URL":"https:\/\/doi.org\/10.1038\/s41586-023-06609-0","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.I., A.C. and D.D.H. are inventors on patent applications related to the development of inhibitors against the SARS-CoV-2 3CL protease. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics and Brii Biosciences, and board director for Vicarious Surgical.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}